- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Influence of Apolipoprotein E Polymorphism on Bezafibrate Treatment Response in Dyslipidemic Patient
-
- Yamada Masamichi
- Department of Internal Medicine, St. Marianna University School of Medicine Tohyoko Hospital
Search this article
Description
To examine the significance of apolipoprotein E (apo E) polymorphism in the hypolipidemic effect of bezafibrate, we evaluated the influence of different apo E phenotypes on serum lipid response to bezafibrate treatment in 58 dyslipidemic patients with WHO phenotypes of llb, IV, or isolated hypo-HDL cholesterolemia. Patients were categorized into one of three groups according to apo E phenotypes of E2 (E2/3, n = 5), E3 (E3/3, n = 35), and E4 (E3/ 4 and E4/4, n=18). After 3 months daily administration of 400 mg bezafibrate, serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDLC) levels changed on average in the E3 group [-8.0% ; p< 0.05 and +1.1% ; not significant (ns), respectively], the E2 group (-18.3% ; p<0.005 and-26.9%; p<0.05, respectively) and the E4 group (+3.8%; ns and +10.1%; ns, respectively). The changes in TC and LDLC levels in the E4 group was significantly less effective compared with those in the E3 (p < 0.05) and E2 groups (p < 0.01). Bezafibrate induced a reduction in serum triglyceride (TG) levels in the E3 group (-50.1%; p < 0.0001), the E2 group (-46.9% ; p < 0.05) and the E4 group (-44.8% ; p < 0.005). An increase in high-density lipoprotein cholesterol (HDLC) levels was also observed in the E3 group (+ 27.5% ; p< 0.0001), the E2 group (+ 35.0% ; ns) and the E4 group (+ 38.8% ; p< 0.005). However, there was no significant difference in the changes of TG and HDLC levels between the groups. These results suggest an important role of apo E polymorphism in modulating serum lipid response to bezafibrate, and phenotyping of apo E helps predict the therapeutic effect of bezafibrate treatment. J Atheroscler Thromb, 1997 ; 4 : 40-44.
Journal
-
- Journal of Atherosclerosis and Thrombosis
-
Journal of Atherosclerosis and Thrombosis 4 (1), 40-44, 1997
Japan Atherosclerosis Society
- Tweet
Details 詳細情報について
-
- CRID
- 1390282679410005120
-
- NII Article ID
- 130004304654
-
- COI
- 1:STN:280:DyaK1c3kt1Kmtw%3D%3D
-
- ISSN
- 18803873
- 13403478
- http://id.crossref.org/issn/13403478
-
- PubMed
- 9583353
-
- Text Lang
- en
-
- Article Type
- journal article
-
- Data Source
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed